2003年9月
Nafamostat mesilate suppresses NF-kappa B activation and NO overproduction in LPS-treated macrophages
INTERNATIONAL IMMUNOPHARMACOLOGY
- ,
- ,
- ,
- ,
- ,
- 巻
- 3
- 号
- 9
- 開始ページ
- 1335
- 終了ページ
- 1344
- 記述言語
- 英語
- 掲載種別
- DOI
- 10.1016/S1567-5769(03)00146-2
- 出版者・発行元
- ELSEVIER SCIENCE BV
Nafamostat mesilate (NM), a clinically used serine protease inhibitor, Suppressed the overproduction of nitric oxide (NO) and the expression of inducible nitric oxide synthase (iNOS) in RAW264.7 murine macrophages treated with lipopolysaccharide (LPS, 100 ng/ml); however, it had little effect oil endothelial NOS (eNOS) in human umbilical vein endothelial cells (HUVEC). Electrophoretic mobility shift assay (EMSA) revealed that LPS activated nuclear factor-kappaB (NF-kappaB) in RAW264.7 cells and that this activation was suppressed by nafamostat mesilate. Western blotting showed that nafamostat mesilate suppressed the phosphorylation and degradation of inhibitor kappaB-alpha (IkappaB-alpha), which holds NF-kappaB in the cytoplasm in an inactivated state. Our observations suggest that nafamostat mesilate is a candidate agent for various diseases such as ischemia-reperfusion, graft rejection, inflammatory diseases, and autoimmune diseases, in which iNOS and/or NF-kappaB are upregulated. (C) 2003 Elsevier B.V. All rights reserved.
- リンク情報
- ID情報
-
- DOI : 10.1016/S1567-5769(03)00146-2
- ISSN : 1567-5769
- Web of Science ID : WOS:000185154100010